Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Revenue (2016 - 2025)

China Pharma Holdings filings provide 16 years of Revenue readings, the most recent being $1.2 million for Q4 2025.

  • On a quarterly basis, Revenue rose 8.11% to $1.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.1 million, a 8.49% decrease, with the full-year FY2025 number at $4.1 million, down 8.49% from a year prior.
  • Revenue hit $1.2 million in Q4 2025 for China Pharma Holdings, up from $756217.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $2.9 million in Q4 2022 to a low of $756217.0 in Q3 2025.
  • Median Revenue over the past 5 years was $1.6 million (2022), compared with a mean of $1.7 million.
  • Biggest five-year swings in Revenue: skyrocketed 33.7% in 2021 and later plummeted 47.25% in 2024.
  • China Pharma Holdings' Revenue stood at $2.9 million in 2021, then increased by 1.09% to $2.9 million in 2022, then decreased by 26.41% to $2.1 million in 2023, then tumbled by 47.25% to $1.1 million in 2024, then grew by 8.11% to $1.2 million in 2025.
  • The last three reported values for Revenue were $1.2 million (Q4 2025), $756217.0 (Q3 2025), and $1.0 million (Q2 2025) per Business Quant data.